MCP
HRTX icon

Moab Capital Partners’s Heron Therapeutics HRTX Stock Holding History

Moab Capital Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-55,734
Closed -$775K – 32
2014
Q1 		$775K Buy
+55,734
New +$745K 0.34% 29

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SC
Savitr Capital San Francisco, California $57M AUM 14.52% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Moab Capital Partners's HRTX Position: Q2 2014 in Review

Moab Capital Partners sold out of Heron Therapeutics (HRTX) in Q2 2014, closing a stake of 55,734 shares — an estimated $775K sold.

Moab Capital Partners first reported a position in HRTX in Q1 2014 and held it in 1 quarter. The position peaked at $775K in Q1 2014. 69 funds tracked by Wall St. Rank hold HRTX as of Q2 2014.

  • Moab Capital Partners reported no remaining Heron Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Moab Capital Partners sold 55,734 Heron Therapeutics shares in Q2 2014, an estimated $775K.
  • Moab Capital Partners first reported a position in Heron Therapeutics in Q1 2014 and held it in 1 quarter.
  • Moab Capital Partners's Heron Therapeutics position peaked at $775K in Q1 2014.
  • 69 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2014.

Based on Moab Capital Partners's 13F filing for Q2 2014, filed 14 Aug 2014.